PCI Pharma Services Capacity Update May 2024: Small Molecule Finished Dosage Form

In this May 2024 edition of the Outsourced Pharma Capacity Update, PCI's Rob Jones outlines how recent investments have greatly increased the available capacity for the development, manufacture, and packaging of highly potent drug products, including solid oral and liquid dosage forms. These investments build on PCI's 35+ years of experience in the handling of potent drug products, and the decade of success of the UK site's original Contained Manufacturing Facility (CMF), which was launched in 2013.